Search
South Korean Biopharmaceutical Behemoth Celltrion Records 45% Jump in Q3 Operating Profit
2025-10-21 /
Read about 0 minute
Author：小编
On Tuesday, South Korean biopharmaceutical firm Celltrion unveiled its unaudited preliminary financial outcomes. The figures revealed that for the third quarter of 2025, the company posted an operating profit of 301 billion Korean won (roughly equivalent to US$211.9 million), marking a 44.9% year - on - year surge. Meanwhile, its sales climbed to 1.02 trillion Korean won, showing a 16.3% increase compared to the same period last year. The company is set to release its final earnings report at a later time.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
